TM
Manifest
Technologies
Individualized brain therapeutics
Platform & Solutions
Manifest Technologies has created the NAIO™ (Neuroscience and Artificial Intelligence Optimized) platform. NAIO™ biomarker engine enables automated integration, processing and analysis of large, complex, multi-modal neuroimaging data sets. The company is building a suite of specific applications out of the NAIO™ platform to meet the needs of both pharmaceutical CNS R&D and health care providers.
Validated Scientific Impact
Manifest was founded by a group of leading experts in computational neuroimaging and psychiatry at Yale University's School of Medicine. Our goal is to transform therapeutic development, diagnosis and treatment for CNS disorders. The company is advancing the world's first AI-powered computational neuroimaging system that quantifies neural and symptom data to create and choose the right therapy for the right patient at the right time.
Manifest's groundbreaking computational neuroimaging NAIO™ platform builds off of a decade of high-impact and validated science out of the founders' laboratories at Yale University School of Medicine supported by $50M+ of NIMH grants. Our science focuses on a range of key applications including biomarker discovery, pharmacological target validation, and patient selection approaches for CNS clinical trials. For a list of selected key publications, click the link below.
Leadership Team
Alan Anticevic, Ph.D.
CEO & Co-Founder
Former Glenn H. Greenberg Associate Professor of Psychiatry & Psychology
Yale University
John Murray, Ph.D.
Scientific Co-Founder
Associate Professor
Psychological & Brain Sciences
Dartmouth College
Markus Helmer, Ph.D.
CTO & Co-Founder
Manifest Technologies
Strategic Advisor
Former CMO
BioHaven Pharmaceuticals
Robert Berman, M. D.
Head of Biomarker Development
Manifest Technologies
Jie Lisa Ji, Ph.D.
Head of Platform
Assistant Professor
Computer Science
University of Ljubljana
Jure Demšar, Ph.D.
Advisory Team
David Gray, Ph.D.
R&D Strategy
CSO
Vigil Neuro
Philip Heifetz, MBA
Business Strategy
Narberth Ventures
Ariane Tom, Ph.D.
Financing Strategy
Founding Partner
Kaleida Capital
Anshu Vaish, M.D.
Client & Product Strategy
COO
Stealth Healthtech
Matt Glasser, M.D.
MR Biomarker Strategy
Assistant Professor
Neurology
Washington Uni. in St. Louis
Jacob Vogel, Ph.D.
PET Biomarker Strategy
Associate Senior Lecturer
Faculty of Medicine
Lund University
Grega Repovs, Ph.D.
Analytics Strategy
Professor of Psychology
University of Ljubljana
